Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Investigational Product 1 · 1 trial · 2 indications
Evaluation PK
Evaluation PK
| Arm | Type | Description |
|---|---|---|
| Arm A | EXPERIMENTAL | - |
| Arm B | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Investigational Product 1 | DRUG | UIC202601 1Tab/day for 7 days |
| Investigational Product 2 | DRUG | UIC202602 1Tab/day for 7 days |
| Investigational Product 1 + Investigational Product 2 | DRUG | UIC202601+UIC202602 2Tab/day for 7 days |
Inclusion Criteria: * Subjects aged 19 years or older and less than 55 years at the screening visit. * Subjects with a body weight of at least 50 kg (at least 45 kg for females) and a body mass index (BMI) of 18.0 kg/m² or higher and 30.0 kg/m² or lower at the screening visit. BMI (kg/m²) = Body w...
Investigational Product 1 is being developed for the treatment of hypertension, a cardiovascular condition. It is currently in Phase 1 clinical development and is being studied in healthy volunteers to evaluate its safety and tolerability.
Investigational Product 1 is being developed by United Therapeutics Corporation, a biopharmaceutical company listed on the NASDAQ under the ticker symbol UTHR.
Investigational Product 1 is in Phase 1 clinical development. It is an investigational small molecule and has not yet been approved by regulatory authorities. A Phase 1 trial is currently recruiting participants.
Investigational Product 1 is being studied in a Phase 1 clinical trial with the identifier NCT07682948. This is a randomized, open-label, two-arm, two-period, multiple-dose study in healthy volunteers to evaluate pharmacokinetic drug-drug interactions, safety, and tolerability.
The Phase 1 clinical trial for Investigational Product 1 involves the evaluation of two investigational drugs, UIC202601 and UIC202602, in healthy volunteers. The trial is designed to assess potential drug-drug interactions between these two agents.